CONTENTS:
• Editorial: The WHO global strategy to reduce the harmful use of alcohol. Chick J., p. 223.
• Biological mechanisms in alcohol dependence--new perspectives. Hillemacher T., p. 224-230.
• Personalized addiction treatment: how close are we? Oslin D., p. 231-232.
• Acetate-dependent mechanisms of inborn tolerance to ethanol. Zimatkin S.M., Oganesian N.A., Kiselevski Y.V., Deitrich R.A., p. 233-238.
• Ceftriaxone, a Beta-lactam antibiotic, reduces ethanol consumption in alcohol-preferring rats. Sari Y., Sakai M., Weedman J.M., Rebec G.V., Bell R.L., p. 239-246.
• Amino-terminal pro-B-type brain natriuretic Peptide: screening for cardiovascular disease in the setting of alcoholism. Hofer P., Syeda B., Bergler-Klein J., Friedrich F., Lesch O.M., Vyssoki B., et al., p. 247-252.
• A Parsimonious, Integrative Model of Key Psychological Correlates of UK University Students' Alcohol Consumption. Atwell K., Abraham C., Duka T., p. 253-260.
• Drinking Motives among Spanish and Hungarian Young Adults: A Cross-National Study. Nemeth Z., Urban R., Kuntsche E., San Pedro E.M., Roales Nieto J.G., Farkas J., et al., p. 261-269.
• Alcohol Use Disorders and Hazardous Drinking among Undergraduates at English Universities. Heather N., Partington S., Partington E., Longstaff F., Allsop S., Jankowski M., et al., p. 270-277.
• Urinary ethyl glucuronide and ethyl sulfate testing for detection of recent drinking in an outpatient treatment program for alcohol and drug dependence. Dahl H., Voltaire Carlsson A., Hillgren K., Helander A., p. 278-282.
• Different methods of early identification of risky drinking: a review of clinical signs. Reinholdz H.K., Bendtsen P., Spak F., p. 283-291.
• Level and Change in Alcohol Consumption, Depression and Dysfunctional Attitudes among Females Treated for Alcohol Addiction. Gjestad R., Franck J., Hagtvet K.A., Haver B., p. 292-300.
• Comparison of the Relationships of Alcohol Intake with Atherosclerotic Risk Factors in Men with and without Diabetes Mellitus. Wakabayashi I., p. 301-307.
• Predictors for the efficacy of naltrexone treatment in alcohol dependence: sweet preference. Laaksonen E., Lahti J., Sinclair J.D., Heinala P., Alho H., p. 308-311.
• Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Addolorato G., Leggio L., Ferrulli A., Cardone S., Bedogni G., Caputo F., et al., p. 312-317.
• Alcohol Withdrawal Syndrome: Symptom-Triggered versus Fixed-Schedule Treatment in an Outpatient Setting. Elholm B., Larsen K., Hornnes N., Zierau F., Becker U., p. 318-323.
• Sociodemographic correlates of transitions from alcohol use to disorders and remission in the sao paulo megacity mental health survey, Brazil. Silveira C.M., Viana M.C., Siu E.R., Guerra de Andrade A., Anthony J.C., Andrade L.H., p. 324-332.
• Assessing the Dimensionality of Lifetime DSM-IV Alcohol Use Disorders and a Quantity-Frequency Alcohol Use Criterion in the Australian Population: a Factor Mixture Modelling Approach. McBride O., Teesson M., Baillie A., Slade T., p. 333-341.
• Risk Factors for Alcohol-specific Hospitalizations and Deaths: Prospective Cohort Study. Poikolainen K., Paljarvi T., Makela P., p. 342-348.
• Age, period and cohort analysis of light and binge drinking in Finland, 1968-2008. Harkonen J.T., Makela P., p. 349-356.
• Predicting and measuring premises-level harm in the night-time economy. Moore S.C., Brennan I., Murphy S., p. 357-363.
• Inpatient detoxification procedure and facilities: financing considerations from an eastern European perspective. Jovanovic M., Jakovljevic M., p. 364-365.